Drug costs,treatment opportunities,specialist experience.
Find your reason to consider China.
Looking to reduce drug costs, find a matched new medicine or seek treatment with less tissue trauma? Start with your needs, explore China's specific value and turn Shanghai care into a clear next step.
CAR-T cell therapy
Lower costs and faster progress towards treatment. Explore specific products and complete treatment arrangements alongside China's active research and clinical resources.
Explore CAR-T treatment4–8 weeks to progress to infusionSinoUnited's published pathway example; complete trip approximately two months.
Hospital package approximately 1/3 of comparable Western treatment costsSinoUnited's public comparison; individual costs and timelines require assessment and confirmation.
22 treatment themes below, plus the CAR-T feature above.
No matching treatment themes found.
Try a disease, medicine or gene name, or contact us directly to discuss your situation.
Innovative medicines and combination regimens
Explore by specific medicine, condition and treatment stage, with approval-based access and price advantages explained individually.
Make medication more affordable
Published Chinese prices for the same medicine can be much lower. Review the specific figures, then compare your actual budget.
- Explore treatment
Fruquintinib treatment in China
Reduce the burden of subsequent targeted therapy: a historical published Chinese price calculates to approximately ¥7,541 for 5mg × 21 capsules, not a full-course price. Shanghai has pivotal-study specialists.
- Explore treatment
Toripalimab: recurrent or metastatic nasopharyngeal cancer
Same drug, 240mg: approximately ¥2,439 in China versus historical US WAC of approximately US $8,892. Years and pricing bases differ; actual total costs are calculated separately.
- Explore treatment
Zanubrutinib: previously treated CLL/SLL and other blood cancers
Calculated 30-day consumption in China: approximately ¥10,007; UK list price for the same drug and quantity: £4,928.65. Pricing bases differ; whole-bottle purchases and follow-up need separate calculation.
Seek an opportunity for the next treatment step
Beyond your current regimen, medicines and combinations approved in China may address your specific treatment challenge.
- Explore treatment
Ivonescimab treatment in China
Seek longer disease control: PFS was 11.1 versus 5.8 months in a specific first-line lung cancer study, not overall survival. Shanghai has study-leading specialists.
- Explore treatment
Sacituzumab tirumotecan: previously treated triple-negative breast cancer
For progression after several treatment lines, explore a matched TROP2 ADC in China; requirements include at least two systemic treatments.
- Explore treatment
Disitamab vedotin plus toripalimab: first-line urothelial cancer
HER2 IHC 1+ can also match a first-line ADC plus immunotherapy regimen. The study showed improved survival versus platinum chemotherapy; benefit varies.
- Explore treatment
Cadonilimab combination: first-line persistent, recurrent or metastatic cervical cancer
PD-L1-negative patients also have a first-line bispecific antibody combination pathway. Wu Xiaohua's Shanghai team has relevant pivotal-study experience; appointments need confirmation.
- Explore treatment
Trastuzumab rezetecan: HER2-mutated non-small cell lung cancer
After progression of treated HER2-activating-mutated lung cancer, consult in Shanghai about a matched ADC. Lu Shun's team led the study; lung toxicity requires particular attention.
After resistance, keep looking for a path forward
Use the specific alteration in your genetic report to identify a targeted next step.
- Explore treatment
Savolitinib + osimertinib treatment in China
Continue targeted therapy for MET amplification-related resistance: investigator-assessed PFS for all SACHI patients was 8.2 versus 4.5 months. Shanghai has specialists involved in the research.
- Explore treatment
Olverembatinib: resistant CML and the T315I mutation
Further targeted treatment for resistant CML, connecting a Chinese-developed medicine with long-term monitoring
- Explore treatment
Vebreltinib: PTPRZ1-MET fusion high-grade glioma
Match a targeted medicine to recurrent glioma with a specific fusion, alongside brain reassessment and supportive care
- Explore treatment
Glecirasib: KRAS G12C-mutated lung cancer
For KRAS G12C lung cancer after systemic therapy, explore a Chinese-developed oral medicine and ongoing prescriptions
- Explore treatment
Sunvozertinib: EGFR exon20ins-mutated lung cancer
Further targeted treatment for an uncommon EGFR insertion mutation, with Chinese-developed supply and cross-border medication continuity
- Explore treatment
Taletrectinib: ROS1-positive lung cancer
Connect with Shanghai teams involved in TRUST-I to plan ROS1 treatment before targeted therapy or after crizotinib
- Explore treatment
Repotrectinib: NTRK fusion solid tumours
Further targeted treatment for NTRK fusion solid tumours, including the studied prior-TRK-treatment population
Other treatment techniques
From organ preservation, donor difficulties and scarce technologies to specialist teams' research experience.
Explore according to your treatment needs
Each treatment has its own eligibility, cost scope and relevant teams.
- Explore treatment
HIFU / Haifu for uterine fibroids
Extracorporeal fibroid ablation to seek uterine preservation and avoid an abdominal incision; imaging and acoustic pathway criteria apply.
- Explore treatment
Haploidentical haematopoietic stem cell transplantation
Assess parents, children and other relatives as donors to expand leukaemia transplant options; not every relative is suitable.
- Explore treatment
Carbon-ion radiotherapy: recurrent nasopharyngeal cancer
Explore carbon-ion re-irradiation for recurrent nasopharyngeal cancer in Shanghai; cumulative doses and fatal bleeding risk require assessment.
- Explore treatment
Advanced gastrointestinal endoscopy: ESD / EFTR / POEM
Seek a more limited treatment for suitable gastrointestinal lesions in Shanghai while preserving organs; achalasia needs separate assessment for swallowing improvement.
- Explore treatment
FOLFOX hepatic arterial infusion chemotherapy for selected liver cancers
For eligible large liver cancers, seek tumour shrinkage and possible subsequent resection through hepatic arterial infusion; surgery is not guaranteed.
- Explore treatment
Hip replacement
Use the published RMB 20,000–30,000 total-cost reference as a budgeting start for less hip pain and better mobility; not a Shanghai foreign-patient quote.
- Explore treatment
Proton radiotherapy
Assess reduced normal-tissue radiation in Shanghai, with a published course reference of RMB 170,000. Individual dose benefits and total foreign-patient costs need separate confirmation.
This page presents treatment pathways for further assessment, not an efficacy ranking. Chinese approval does not mean no other treatments exist in your country. Confirm costs against your individual self-funded budget without Chinese insurance.